Efficacy and Effectiveness of the Meningococcal Conjugate Group A Vaccine MenAfriVac(®) in Preventing Recurrent Meningitis Epidemics in Sub-Saharan Africa

For more than a century, epidemic meningococcal disease mainly caused by serogroup A Neisseria meningitidis has been an important public health problem in sub-Saharan Africa. To address this problem, an affordable meningococcal serogroup A conjugate vaccine, MenAfriVac(®), was developed specifically...

Descripción completa

Detalles Bibliográficos
Autor principal: Viviani, Simonetta
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9027557/
https://www.ncbi.nlm.nih.gov/pubmed/35455366
http://dx.doi.org/10.3390/vaccines10040617

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9027557/
https://www.ncbi.nlm.nih.gov/pubmed/35455366
http://dx.doi.org/10.3390/vaccines10040617

Ejemplares similares